Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non-small Cell Lung Cancer: TORG1937 (DATE Study).

Shinji Nakamichi Kaoru Kubota Toshihiro Misumi Tetsuro Kondo Shuji Murakami Yoshimasa Shiraishi Hisao Imai Daijiro Harada Kazutoshi Isobe Hidetoshi Itani Saori Takata Kazuyoshi Kuwano Yuki Misumi Satoshi Ikeda Tetsuhiko Asao Naoki Furuya Shinobu Hosokawa Yumiko Kobayashi Yuichi Takiguchi Hiroaki Okamoto

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)

Our study met the primary endpoint. The incidence of pneumonitis was similar to that of a Japanese subset in the PACIFIC study. Our data support the efficacy and safety of durvalumab administered immediately after the completion of CCRT for patients with unresectable stage III NSCLC.

Keyphrases

locally advanced
phase ii study
small cell lung cancer
randomized controlled trial
squamous cell carcinoma
radiation therapy
clinical trial
study protocol
deep learning